Paeds Vivas · endocrinology-diabetes-and-growth
Hyperthyroidism and Graves disease — branching viva
Branching viva on distinguishing thyrotoxicosis from hyperthyroidism, confirming Graves disease through a suppressed TSH, raised free T4 and a positive TSH-receptor antibody, delivering the beta-blocker bridge and carbimazole-first-line strategy, holding propylthiouracil for thyroid storm and first-trimester pregnancy, recognising transient neonatal thyrotoxicosis, and reaching definitive radioactive iodine or surgery for relapse.
On this page
Study tools
Target exams
Opening framework
My framework has three layers. First, the recognition — a suppressed TSH with a raised free T4 confirms thyrotoxicosis, and a positive TSH-receptor antibody confirms Graves disease and makes the radioiodine scan unnecessary in most children. Second, the mechanism — a stimulating antibody switches on the TSH receptor without any pituitary brake, driving hormone synthesis and the beta-adrenergic storm that defines the clinical picture. Third, the management — a beta-blocker bridges the symptoms while carbimazole or methimazole controls the gland, and propylthiouracil is held for thyroid storm and first-trimester pregnancy because of fulminant hepatotoxicity in children. [1]
References6ShowHide
- [1]Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 2016.PMID 27521067
- [3]Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol, 2023.PMID 36848916
- [5]Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Léger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab, 2008.PMID 18628515
- [6]Léger J, Carel JC. MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Eur J Endocrinol, 2017.PMID 28381452
- [9]Rivkees SA, Mattison DR. Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol, 2009.PMID 19946400
- [11]Polak M. Hyperthyroidism in early infancy: pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid, 1998.PMID 9920374